Barclays PLC Sells 777,507 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Barclays PLC reduced its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 89.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 95,767 shares of the company’s stock after selling 777,507 shares during the quarter. Barclays PLC’s holdings in Karyopharm Therapeutics were worth $79,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Point72 DIFC Ltd bought a new stake in Karyopharm Therapeutics during the second quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $143,000. Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $167,000. Exchange Traded Concepts LLC boosted its holdings in shares of Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after buying an additional 76,510 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KPTI. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Piper Sandler raised their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Price Performance

NASDAQ:KPTI opened at $0.72 on Friday. The company has a market cap of $90.35 million, a P/E ratio of -0.63 and a beta of 0.07. The firm’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $0.82. Karyopharm Therapeutics Inc. has a one year low of $0.58 and a one year high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same period in the prior year, the company earned ($0.30) earnings per share. As a group, equities research analysts expect that Karyopharm Therapeutics Inc. will post -0.94 earnings per share for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).